Development of a polyclonal antibody that detects phosphorylated glutamate receptor 1 protein (GluA1 pS567)
Development of a Rabbit Polyclonal Antibody for the pT707 Phosphorylated Site of Neuroligin-4 (NLHN4)
Treatment of Immune-mediated Brain Swelling with Combined Anti-LFA1/VLA4 Therapy
Development of an Antibody, VA-17, that Detects All Forms of Oxytocin in Radioimmunoassay (RIA)
The Generation and Use of Novel Anti-mitofusin 1 Polyclonal Antibodies
Nanobody Therapeutics for SARS-CoV2
Monoclonal Antibody that Detects a Subclass of Dog IgG—for Diagnostic and Research Applications
Replicating RNA Vaccine For Crimean-Congo Hemorrhagic Fever Virus
Crimean-Congo hemorrhagic fever (CCHF) is a deadly hemorrhagic fever having a high mortality rate. The disease results from infection of an individual by Crimean-Congo hemorrhagic fever virus (CCHFV), which is a tick-borne bunyavirus endemic in Southern and Eastern Europe, Africa, the Middle East, and Asia. Geographically, case distribution is consistent with the range of Hyalomma genus ticks, the main reservoir of CCHFV, and is likely to expand due to climate change. Humans may be infected from tick bites, through contact with infected animals or animal tissue.
Engineered Cell-Penetrating Monoclonal Antibody for Universal Influenza Immunotherapy
Influenza remains a burden on public health, as current treatments of viral infections remain ineffective due to frequent virus mutations. Many current influenza treatments rely on targeting surface viral glycoproteins. Unfortunately, these glycoproteins are primary targets of the immune system, which results in increased selection pressure and mutational rate, leading to the well-known seasonal variation of influenza virus.